Red Clover

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: skin detox inflammation

Research Overview

Research on red clover (Trifolium pratense) has focused primarily on its phytoestrogenic isoflavones (notably formononetin and daidzein) and their potential clinical relevance to menopausal vasomotor symptoms. Human evidence is dominated by randomized controlled trials and systematic reviews/meta-analyses of phytoestrogen supplements, including red clover extracts such as Promensil, assessing outcomes like hot flush frequency and composite symptom scores (e.g., Kupperman index). A second, more preclinical line of work examines mechanistic and disease-modifying effects of individual red clover isoflavones in experimental models, including anti-inflammatory and neuroprotective actions; for example, formononetin has been reported in a rat middle cerebral artery occlusion model to reduce infarct size and inflammatory mediators, with associated downregulation of JAK2/STAT3 signaling and inflammasome-related proteins.

The strongest evidence base relates to menopausal hot flushes, but conclusions are mixed and depend on the phytoestrogen source and formulation. Across phytoestrogen trials as a broad category, meta-analytic findings suggest a modest reduction in hot flush frequency versus placebo, with no clear signal of serious short-term adverse effects. However, when focusing specifically on red clover extract trials pooled in a major systematic review, the overall effect on hot flush frequency was not statistically significant compared with placebo, and placebo responses were substantial. More generally, narrative reviews of isoflavones suggest potential benefits for bone health and possible effects on cancer risk markers, but these conclusions are described as not fully conclusive and are limited by heterogeneity across studies and designs; safety signals reported are typically mild (often gastrointestinal) in the available literature, with limited evidence of overt estrogenic stimulation of endometrium/vagina over follow-up up to about two years in the reviewed trials.

Key gaps include the need for larger, well-powered, longer-duration randomized trials specifically of standardized red clover preparations (with quantified isoflavone profiles and bioavailability) using harmonized endpoints for vasomotor symptoms and clinically meaningful outcomes beyond symptom counts. Additional research is also needed to clarify inter-individual variability (e.g., metabolism and estrogen receptor–related responsiveness), comparative effectiveness versus other phytoestrogen sources (such as genistein-rich preparations), and longer-term safety in populations where estrogenic activity is a concern. Finally, promising mechanistic findings for isolated compounds like formononetin in preclinical neuroinflammation/ischemia models require translational work to determine relevance to humans, including pharmacokinetics, target engagement, and confirmation in clinical settings.

1. What conditions has Red Clover been studied for?

  • Menopausal vasomotor symptoms (hot flushes/night sweats) via red clover isoflavone extracts (e.g., Promensil) and more broadly “phytoestrogens” (which include red clover and soy isoflavones).

  • Cerebral ischemia-reperfusion injury / stroke models (preclinical): formononetin (a red clover–derived isoflavone) studied in a rat MCAO model for anti-inflammatory neuroprotection.

  • Bone health/osteoporosis (postmenopausal): discussed in a review of isoflavones (including red clover as a source), with overall evidence described as beneficial but not fully conclusive.

  • Cancer-related outcomes (risk modulation/chemoprevention): reviews discuss isoflavones (including those found in red clover) in relation to breast/endometrial cancer risk, but emphasize uncertainty and need for more studies.

  • Cardiovascular risk factors: reviewed for isoflavones broadly; one review states soy isoflavones do not show a meaningful protective effect on cardiovascular risk (red clover not specifically proven).

  • Metabolic effects (lipids/glucose, diabetes-related): discussed mainly for individual isoflavones (e.g., daidzein, biochanin A) as having potential lipid/glucose modulatory activity; human evidence is not established in the provided abstracts.

  • Agricultural/animal nutrition: red clover silage studied in dairy cows for effects on milk production, nitrogen use efficiency, and milk fatty acid profile (not a human health condition, but included in the abstracts).

2. Does it work in treating those conditions? Summarize the evidence.

  • Hot flushes/vasomotor menopausal symptoms: Evidence is mixed and depends on what “phytoestrogen” is used.

    • A 2013 meta-analysis of 15 RCTs of oral phytoestrogens found a significant reduction in hot flush frequency vs placebo (pooled mean difference reported as 0.89; p < 0.005), but no significant improvement in Kupperman Index (p = 0.110).

    • A Cochrane review (43 RCTs; 4,364 participants) concluded there is no conclusive evidence that phytoestrogen supplements reduce hot flushes/night sweats overall. Specifically for Promensil (red clover extract), pooled results from five trials showed no statistically significant difference in daily hot flush frequency vs placebo (MD -0.93; 95% CI -1.95 to 0.10).

    • The same Cochrane review noted that genistein concentrates (>30 mg/day) more consistently reduced hot flush frequency in individual trials—this points to potential benefit for certain isoflavone preparations, but this is not specific proof for red clover extracts.

  • Cerebral ischemia-reperfusion injury (stroke) in animals: In a rat MCAO model, formononetin improved neurological deficit scores and reduced infarct volume and inflammatory markers (e.g., plasma IL-18 and TNF-α; brain IL-6 and IL-1β mRNA), and reduced activation of JAK2/STAT3 and downstream inflammasome-related proteins (NLRP3, ASC, cleaved caspase-1, cleaved IL-1β). This supports a plausible anti-inflammatory mechanism in animals, but it is not clinical evidence in humans.

  • Bone health/osteoporosis: A review states there is scientific evidence suggesting benefit of isoflavones on bone health in postmenopausal women, but results are not entirely conclusive due to discrepancies and heterogeneity; more RCTs are needed. The abstracts do not provide red clover–specific RCT outcomes.

  • Cancer and cardiovascular outcomes: The provided abstracts are largely narrative/review-level and do not establish that red clover supplementation treats or prevents these conditions. One review suggests isoflavones may reduce risk of some cancers (e.g., breast/endometrial) but emphasizes need for confirmation; it also states soy isoflavones do not meaningfully protect cardiovascular risk (not red clover-specific).

3. What health benefits does it have?

  • Potential relief of menopausal hot flushes: Some pooled RCT evidence across phytoestrogens suggests reduced hot flush frequency, but red clover extract (Promensil) specifically did not show a clear statistically significant benefit in pooled Cochrane analysis.

  • Estrogen-like (phytoestrogen) activity: Isoflavones in red clover (e.g., formononetin, daidzein, biochanin A) have structures/actions similar to estradiol as described in the abstracts, which is the rationale for menopausal symptom and bone-health research.

  • Anti-inflammatory and neuroprotective signals (preclinical): In rats with cerebral ischemia-reperfusion injury, formononetin reduced inflammatory cytokines and signaling (JAK2/STAT3; NLRP3 inflammasome-related proteins) alongside improved tissue/functional outcomes.

  • Possible bone health support (indirect evidence): Reviews of isoflavones overall suggest beneficial effects on bone health in postmenopausal women, though not fully consistent across studies.

  • Other proposed benefits (insufficient clinical confirmation in the provided abstracts): Reviews mention potential metabolic (glucose/lipid modulation) and cancer-related effects for isoflavones, but the abstracts do not provide strong red clover–specific human efficacy data.

4. Does it have any downsides or side effects?

  • Side effects in menopausal RCTs of phytoestrogens: A meta-analysis of 15 RCTs found no significant difference in side-effect likelihood between phytoestrogens and placebo (p = 0.175).

  • Endometrial/vaginal stimulation (estrogenic adverse effects): The Cochrane review reported no evidence that phytoestrogen treatments caused estrogenic stimulation of the endometrium or vagina or other adverse effects when used for up to two years in the included trials (noting that trial limitations exist).

  • Placebo effect and study limitations: The Cochrane review highlighted a strong placebo effect (1% to 59% reduction in hot flush frequency with placebo) and that many trials were small and at high risk of bias, which limits confidence in both benefits and harms.

  • General tolerability of isoflavones: A review states isoflavones appear safe overall, with the most common adverse effects being mild gastrointestinal symptoms.

  • Human evidence gaps for specific red clover constituents: A biochanin A overview notes it is commercially available and used in supplements, but that its activity has not been adequately evaluated in humans (implying uncertainty about both efficacy and risk at supplement doses).

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses (no genotype-stratified outcomes, responder analyses by genetic variants, or gene–supplement interaction data) for red clover or its isoflavones.

  • What can be said from these abstracts: No evidence is presented that specific genetic variants make red clover more beneficial or more harmful.

  • Key limitation: Even where mechanisms are proposed (e.g., formononetin affecting JAK2/STAT3 signaling in rats), the abstracts do not connect these pathways to human genetic variation or differential clinical response.

References

  1. Formononetin protects against inflammation associated with cerebral ischemia-reperfusion injury in rats by targeting the JAK2/STAT3 signaling pathway.
    Li Yu, Yangyang Zhang, Qianqian Chen, Yu He, Huifen Zhou, Haitong Wan, Jiehong Yang (2022) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review.
    M-N Chen, C-C Lin, C-F Liu (2015) - Climacteric : the journal of the International Menopause Society
  3. Focus on Formononetin: Anticancer Potential and Molecular Targets.
    Samantha Kah Ling Ong, Muthu K Shanmugam, Lu Fan, Sarah E Fraser, Frank Arfuso, Kwang Seok Ahn, Gautam Sethi, Anupam Bishayee (2019) - Cancers
  4. Phytoestrogens for menopausal vasomotor symptoms.
    Anne Lethaby, Jane Marjoribanks, Fredi Kronenberg, Helen Roberts, John Eden, Julie Brown (2013) - The Cochrane database of systematic reviews
  5. Scientific Evidence Supporting the Beneficial Effects of Isoflavones on Human Health.
    Saioa Gómez-Zorita, Maitane González-Arceo, Alfredo Fernández-Quintela, Itziar Eseberri, Jenifer Trepiana, María Puy Portillo (2020) - Nutrients
  6. Daidzein from Dietary Supplement to a Drug Candidate: An Evaluation of Potential.
    Mohammed Ubaid, Salauddin, Md Andalib Shadani, S M Kawish, Mohammed Albratty, Hafiz A Makeen, Hassan A Alhazmi, Asim Najmi, Khalid Zoghebi, Maryam A Halawi, Abuzer Ali, Md Shamsher Alam, Zeenat Iqbal, Mohd Aamir Mirza (2023) - ACS omega
  7. Perspectives Regarding the Role of Biochanin A in Humans.
    Chen Yu, Peng Zhang, Lixin Lou, Yang Wang (2019) - Frontiers in pharmacology
  8. Anti-Inflammatory and Antioxidant Effects of Anthocyanins of
    Sang Gil Lee, Cindi R Brownmiller, Sun-Ok Lee, Hye Won Kang (2020) - Nutrients
  9. Feeding lower-protein diets based on red clover and grass or alfalfa and corn silage does not affect milk production but improves nitrogen use efficiency in dairy cows.
    M R Chowdhury, R G Wilkinson, L A Sinclair (2023) - Journal of dairy science
  10. Reducing dietary protein and supplementation with starch or rumen-protected methionine and its effect on performance and nitrogen efficiency in dairy cows fed a red clover and grass silage-based diet.
    M R Chowdhury, R G Wilkinson, L A Sinclair (2024) - Journal of dairy science
  11. Enrichment of milk antioxidant activity by dietary supplementation of red clover isoflavone in cows and its improvement on mice intestinal health.
    Xiaoyin Zhang, Zhanbo Xiong, Shiqi Zhang, Kexin Li, Ying Bu, Nan Zheng, Shengguo Zhao, Jiaqi Wang (2024) - Food chemistry
  12. The Effect of Traditional and Cyclodextrin-Assisted Extraction Methods on
    Jurga Andreja Kazlauskaite, Liudas Ivanauskas, Mindaugas Marksa, Jurga Bernatoniene (2022) - Antioxidants (Basel, Switzerland)
  13. Efficacy of plant-derived dietary supplements in improving overall menopausal symptoms in women: An updated systematic review and meta-analysis.
    Mi Ra Oh, Jae Ho Park, Seon Kyeong Park, Soo Hyun Park (2024) - Phytotherapy research : PTR
  14. Herbal Products Used in Menopause and for Gynecological Disorders.
    Maša Kenda, Nina Kočevar Glavač, Milan Nagy, Marija Sollner Dolenc, On Behalf Of The Oemonom (2021) - Molecules (Basel, Switzerland)
  15. Estrogenic Plants: to Prevent Neurodegeneration and Memory Loss and Other Symptoms in Women After Menopause.
    Valentina Echeverria, Florencia Echeverria, George E Barreto, Javier Echeverría, Cristhian Mendoza (2021) - Frontiers in pharmacology
  16. Botanical modulation of menopausal symptoms: mechanisms of action?
    Atieh Hajirahimkhan, Birgit M Dietz, Judy L Bolton (2013) - Planta medica
  17. Daidzein and Genistein: Natural Phytoestrogens with Potential Applications in Hormone Replacement Therapy.
    Aekkhaluck Intharuksa, Warunya Arunotayanun, Mingkwan Na Takuathung, Siripat Chaichit, Anchalee Prasansuklab, Kamonwan Chaikhong, Buntitabhon Sirichanchuen, Suthunya Chupradit, Nut Koonrungsesomboon (2025) - International journal of molecular sciences
  18. Trifolium species-derived substances and extracts--biological activity and prospects for medicinal applications.
    Joanna Kolodziejczyk-Czepas (2012) - Journal of ethnopharmacology
  19. A Review of the Phytochemistry and Bioactivity of Clover Honeys (
    Sharmin Sultana, Kevin Foster, Lee Yong Lim, Katherine Hammer, Cornelia Locher (2022) - Foods (Basel, Switzerland)
  20. Herbal preparations for the treatment of hair loss.
    Ana Zgonc Škulj, Nina Poljšak, Nina Kočevar Glavač, Samo Kreft (2020) - Archives of dermatological research


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!